Methods of administering Anti-TNF(ALPHA) antibodies

MYPI2002002103A0Inactive Publication Date: 2002-12-08ABBVIE BIOTECHNOLOGY LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2002002103
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2001-06-08
Filing Date
2002-06-06
Publication Date
2002-12-08
Estimated Expiration
Not applicable · inactive patent
Patent Text Reader

Abstract

METHODS OF TREATING DISORDERS IN WHICH TFNa ACTIVITYIS DETRIMENTALVIA BIWEEKLY, SUBCUTANEOUS ADMINISTRATION OF HUMAN ANTIBODIES, PREFERABLY RECOMBINANT HUMAN ANTIBODIES, THAT SPECIFICALLY BIND TO HUMAN TUMOR NECROSIS FACTOR a (hTNFa) ARE DISCLOSED. THE ANTIBODY MAY BE ADINISTERED WITH OR WITHOUTMETHOTREXATE. THESE ANTIBODIES HAVE HIGH AFFINITY FOR hTNFa(E.G.,KD=10-8 M OR LESS), A SLOW OFF RATE FOR hTNFa DISSOCIATION (E.G.,KOFF=10-3 SEC-1 OR LESS) AND NEUTRALIZE hTNFa ACTIVITY IN VITRO AND IN VIVO. AN ANTIBODY OF THE INVENTION CAN BE A FULL-LENGHT ANTIBODY OR AN ANTIGEN-BINDING PORTION THEREOF. KITS CONTAINING A PHARMACEUTICAL COMPOSITION AND INSTRUCTIONS FOR DOSING, AND PRELOADED SYRINGES CONTAINING PHARMACEUTICAL COMPOSITIONS ARE ALSO ENCOMPASSED BY THE INVENTION.
Need to check novelty before this filing date? Find Prior Art